101. Metabolic syndrome, insulin resistance and the risk of cardiovascular disease in HIV patients undergoing antiretroviral therapy
- Author
-
Irina Lăpădat, Adriana Hristea, Raluca Mihăilescu, Violeta Molagic, Raluca Năstase, Daniela Munteanu, Cristina Popescu, Victoria Aramă, Cătălin Tilişcan, Mirela Dinu, Sorin Ștefan Aramă, Daniela Adriana Ion, Adrian Streinu-Cercel, Mihai Lazăr, Ruxandra Moroti, Mihaela Rădulescu, Ana Maria Tudor, and Anca-Ruxandra Negru
- Subjects
medicine.medical_specialty ,education.field_of_study ,Pathology ,Framingham Risk Score ,business.industry ,Population ,Disease ,medicine.disease ,Antiretroviral therapy ,Insulin resistance ,Infectious Diseases ,Internal medicine ,Tropical medicine ,medicine ,Hiv patients ,Oral Presentation ,Metabolic syndrome ,education ,business - Abstract
We enrolled 103 patients, including 60 males (58.3%) and 43 females (41.7%). The mean age was 32.3±13.3 years (range: 13-65 years). The median Framingham score was 1.2% (IQR=5.8%). Most patients (81.63%) had a low CVR (below 10%) and 18.37% had Framingham score values above 10%. MS and IR prevalences were 16.9% and 61.2%, respectively. CVR in the general population is primarily dependent on age. This observation was valid for our group: the median age was 24 years in people with low CVR, compared with 50 years for those with Framingham score above 10% (p=0.000). None of the antiretroviral drug classes significantly influenced CVR.
- Full Text
- View/download PDF